Phase 3 Trial

Edesa Biotech Inc (NASDAQ: EDSA) has announced additional results from the Phase 2 part of an ongoing Phase 2/3 study of EB05 as a single-dose treatment for hospitalized COVID-19 patients. Related: Edesa Biotech Provides Update For COVID-19 Antibody Trial. Overall, EB05 + Standard of...

Galera Therapeutics Inc (NASDAQ: GRTX) stock has plunged to all-time since its listing in November 2019 in reaction to disappointing data from the Phase 3 ROMAN trial of avasopasem manganese in severe oral mucositis (SOM) patients with locally advanced head and neck cancer (HNC)...

Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) announced topline results from its Phase 3 ATTACK trial of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with infections caused by Acinetobacter baumannii.  Colistin (polymyxin E) is an antibiotic medication used as...

Biogen Inc (NASDAQ: BIIB) has announced topline results from its Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense drug for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The drug failed the primary endpoint on significantly improving...

Phathom Pharmaceuticals Inc (NASDAQ: PHAT) has announced data from the PHALCON-EE Phase 3 trial evaluating vonoprazan versus lansoprazole for erosive esophagitis (EE).  Esophagitis is inflammation, irritation, or swelling of the esophagus lining, which is the tube that runs...

Valneva SE's (NASDAQ: VALN) COVID-19 vaccine elicits a robust immune response with far fewer side effects than the Oxford/AstraZeneca plc's (NASDAQ: AZN) jab, according to Phase 3 trial results. Valneva said its latest trial, Cov-Compare, included around 4,000 participants...

Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK) Phase 3 trial of SRP-9001 for Duchenne muscular dystrophy.  SRP-9001, being developed in partnership with ...

AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease or death in a late-stage study. The drug, a cocktail of two antibodies called AZD7442, reduced the risk of severe COVID...

AbbVie Inc (NYSE: ABBV) has churned out new data for Rinvoq in the hope that adding more evidence will back the JAK inhibitor's megablockbuster potential. Related: AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis. The first study, part of the...

Brickell Biotech Inc (NASDAQ: BBI) has announced positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies of sofpironium bromide gel for primary axillary hyperhidrosis (excessive underarm sweating). The Company plans to file an FDA marketing application...

Cassava Sciences Inc (NASDAQ: SAVA) initiated an initial Phase 3 efficacy study of simufilam, an investigational drug for patients with Alzheimer's disease.  A second Phase 3 efficacy study of simufilam in Alzheimer's disease is expected to begin by year-end. Phase 3...

RedHill Biopharma Ltd (NASDAQ: RDHL) has reported new data from the opaganib global Phase 2/3 study in hospitalized COVID-19 patients with severe pneumonia. Related: What's Happening With RedHill Biopharma's Stock On Tuesday? The data comes from a post-hoc analysis of...

Galapagos NV (NASDAQ: GLPG) has randomized the last patient into the DIVERSITY Phase 3 study of filgotinib in the induction and maintenance of remission in patients with Crohn's Disease (CD). The DIVERSITY study enrolled 1,374 participants. The study evaluates the safety and...

Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics have announced data from a planned interim analysis of Phase 3 MOVe-OUT trial of molnupiravir (MK-4482, EIDD-2801) from 775 COVID-19 patients. Related: Merck's COVID-19 Antiviral Pill Effective Against...

AbbVie Inc (NYSE: ABBV) announced new Phase 3 data analyses of KEEPsAKE-1 and KEEPsAKE-2, evaluating Skyrizi (risankizumab) in adults with active psoriatic arthritis for one year (52 weeks). The results were presented at the European Academy of Dermatology and Venereology (EADV)...